Targeting of Drugs to Cell Surface Receptors

References

• Abuchowski A., McCoy J. R., Palczuk N. C., Van Es T., Davis F. F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977; 252: 3582–3586
   PubMed Web of Science ®Google Scholar
• Allcock H. R., Allen R. W., O'Brien J. P. Antitumor agents synthesized from K2PtCl4 and polymeric or cyclic polyphosphazenes. J. Chem. Soc. Chem. Commun. 1976; 18: 717–724
   Google Scholar
• Appelbaum F. R., Matthews D. C., Eary J. F., Badger C. C., Kellogg M., Press O. W., Martin P. J., Fisher D. R., Nelp W. B., Thomas E. D., Bernstein I. D. The use of radiolabeled anti CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829–833
   PubMed Web of Science ®Google Scholar
• Behr T., Becker W., Hannappel E., Goldenberg D. M., Wolf F. Targeting of liver metastases of colorectal cancer with IgG, F(ab)2, and Fab anti-carcinoembryonic antigen antibodies labeled with 90mTc: the role of metabolism and kinetics. Cancer Res. 1995; 55(Suppl.)5777s–5785s
   Google Scholar
• Bickel U., Yoshikawa T., Landaw E., et al. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA 1993; 90: 2618–2622
   PubMed Web of Science ®Google Scholar
• Blythman H. E., Casellas P., Gros O., Gros P., Jansen F. K., Paolucci F., Pau B., Vidal H. Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. Nature 1981; 290: 145–146
   PubMed Web of Science ®Google Scholar
• Boerman O. C., Tibben J. G., Massuger L. F. A. G., Claessens R. A. M. J., Corstens F. H. M. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispecific monoclonal antibody OC/TR and its parental MOvl8 antibody in experimental ovarian cancer. Anticancer Res. 1995; 15: 2169–2174
   PubMedGoogle Scholar
• Brissinck J., Bemaner C., Moser M., Leo O., Thielemans K. Treatment of mice bearing BCL, lymphoma with bispecific antibodies. J. Immunol. 1991; 147: 4019–4026
   PubMed Web of Science ®Google Scholar
• Chang T. M., Dazord A., Neville D. M. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide complex. II. Biochemical and biological properties of diphtheria toxin fragment A-S-S-human placental lactogen. J. Biol. Chem. 1977; 252: 1515–1522
   PubMed Web of Science ®Google Scholar
• Chang T. M., Neville D. M. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulphide conjugate. I. Synthesis of diphtheria toxin fragment A-S-S-human placental lactogen with methyl-5-bromovalerimidate. J. Biol. Chem. 1977; 252: 1505–1514
   PubMed Web of Science ®Google Scholar
• Davies D. A. L., O'Neill G. J. In vitro and in vivo effects of tumor specific antibodies with chlorambucil. Br. J. Cancer 1973; 28(Suppl. 1)285–298
   Google Scholar
• Decher G., Emmelius M., Ringsdorf H. Synthesis and antitumour activity of daunorubicin-containing polymers. Proc. 26th Micro-symposium on Polymers in Medicine and Biology, PragueCzechoslovakia, 1984; 40–41
   Google Scholar
• De Groen P. C., Wiesner R. H., Krom R. A. F. Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay?. Transplant. Proc. 1988; 20(Suppl.2)374–376
   PubMedGoogle Scholar
• de Harven E., Fradet Y., Connolly J. G., Hanna W., He S., Wang Y., Choi B. C. K., McGroarty R., Bootsma G., Tilups A., Christensen H. Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies. Cancer Res. 1992; 52: 3131–3137
   PubMedGoogle Scholar
• Delaloye B., Bischof-Delaloye A., Buchegger F., von Fliedner V., Grob J.-P., Volant J.-C., Pettavel J., Mach J.-P. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab pr F(ab)2 fragments from monoclonal anti-carcino-embryonic antigen antibodies. Clin. Invest. 1986; 77: 301
   Google Scholar
• De Palazzo I. G., Holmes M., Gercel-Taylor C., Weiner L. M. Antitumor effects of a bispecific antibody targeting CA19–9 antigen and CD16. Cancer Res. 1992; 52: 5713–5719
   PubMed Web of Science ®Google Scholar
• Derbyshire E. J., Wawrzynczak E. J. An anti-mucin immunotoxin BrE-3-ricin A-chain is potently and selectively toxic to human small-cell lung cancer. Int. J. Cancer 1992; 52: 624–630
   PubMedGoogle Scholar
• Dohlsten M., Hedlung G., Akerblom E., Lando P. A., Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc. Natl. Acad. Sci. USA 1991; 88: 9287–9291
   PubMed Web of Science ®Google Scholar
• Dreborg S., Akerblom E. Immunotherapy with monomethoxy polyethylene glycol modified allergens. CRC Crit. Rev. Ther. Drug Carrier Systems. 1990; 6: 315–365
   PubMed Web of Science ®Google Scholar
• Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 1992; 3: 175–210
   PubMed Web of Science ®Google Scholar
• Duncan R., Hume I. C., Yardley H. J. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)mefhacrylamide copolymers. J. Control. Res. 1991; 16: 121–136
   Web of Science ®Google Scholar
• Duncan R., Kopeček J. Soluble synthetic polymers as potential drug carriers. Advances in Polymer Sciences, K. Dušek. Springer-Verlag, Berlin 1984; Vol. 57: 51
   Google Scholar
• Duncan R., Kopečková P., Strohalm J., Hume I. C., Lloyd J. B., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br. J. Cancer 1988; 57: 147–156
   PubMed Web of Science ®Google Scholar
• Duncan R., Seymour L., Scarlett L., Lloyd J. B., Rejmanová P., Kopeček J. Fate of N-(2-hydroxypropyl) methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 1986; 880: 62–71
   PubMed Web of Science ®Google Scholar
• Duncan R., Seymour L. W., O'Hare K. B. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Rel. 1992; 19: 331–346
   Google Scholar
• Ehrlich P. Studies in Immunity. John Wiley & Sons, New York 1906
   Google Scholar
• Eshhar Z., Waks T., Gross G., Schindler D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or dzeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 1993; 90: 720–724
   PubMed Web of Science ®Google Scholar
• Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are oncodevelopmental antigens. Nature 1985; 314: 53–57
   PubMed Web of Science ®Google Scholar
• Ferkol T., Kaetzel Ch. S., Davis P. B. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 1993; 92: 2394–2400
   PubMed Web of Science ®Google Scholar
• Fjeld J. G., Michaelsen T. E., Nustad K. The binding parameters of radiolabelled monoclonal F(ab)2 and Fab fragments relative to immunoglobulin G in reactions with surface-bound antigens. Eur. J. Nucl. Med. 1992; 19: 402–408
   PubMedGoogle Scholar
• Flanagan P. A., Duncan R., Říhová B., Šubr V., Kopeček J. Immunogenicity of protein-N-(2-hydroxypropyl) methacrylamide copolymer conjugates in A/J and B10 mice. J. Bioact. Comp. Polym. 1990; 5: 151–166
   Google Scholar
• Franzmann G., Ringsdorf H. Pharma-kologisch aktive Polymere 12. Depotformen von Chlorambucil durch kovalente Bindung an Polymere. Makromol. Chemistry 1976; 177: 2547–2551
   Google Scholar
• Fritsche R., Mach J. P. Isolation and characterization of carcinoembryonic antigen (CEA) extracted from normal human colonic mucosa. Immunochemistry 1977; 14: 197–204
   PubMedGoogle Scholar
• Garrido M. A., Valdayo M. J., Winkler D. F., Titus J. A., Hecht T. T., Perez P., Segal D. M., Wunderlich J. R. Targeting human T-lym-phocytes with bispecific antibodies to react against human ovarian carcinoma cells in nu/nu mice. Cancer Res. 1990; 50: 4227–4232
   PubMedGoogle Scholar
• Geissler F., Anderson S. K., Venkatesan P., Press O. Intracellular catabolism of radiolabeled anti-u antibodies by malignant B-cells. Cancer Res. 1992; 52: 2907–2915
   PubMedGoogle Scholar
• Gilliland D. G., Steplewski Z., Collier R. J., Mitchell K. F., Chang T. H., Koprowski H. Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA 1980; 77: 4539–4543
   PubMed Web of Science ®Google Scholar
• Gilliland L. K., Clark M. R., Waldmann J. H. Universal bispecific antibody for targeting tumor cells for destruction. Proc. Natl. Acad. Sci. USA 1988; 85: 7719–7723
   PubMedGoogle Scholar
• Goldenberg D. M. Challenge to the therapy of cancer with monoclonal antibodies. J. Natl. Cancer Inst. 1991; 83: 78–79
   PubMedGoogle Scholar
• Gregoriadis G. Liposomes in therapeutic and preventive medicine: the development of the drug carrier concept. Ann. NY. Acad. Sci. 1978; 308: 343–370
   PubMedGoogle Scholar
• Grim Y., Kopeček J. Bioadhesive water-soluble polymeric drug carriers for site-specific oral drug delivery. Synthesis, characterization and release of 5-aminosalicylic acid by Streptococcus faecium in vitro. New Polym. Mater. 1991; 3: 49–59
   Web of Science ®Google Scholar
• Haisma H. J., Boven E., van Muijen M. Analysis of a conjugate between anticarcino-embryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immunother. 1991; 34: 343–352
   Google Scholar
• Hasan T. Selective phototoxicity using monoclonal antibody-chromophore conjugates. Proc. SPIE 1988; 997: 42–47
   Google Scholar
• Hollander N. Ar-1 negative and Ly-1 negative variants of T cells produce interleukin-2 in response to mitogens. J. Immunol. 1987; 139: 437–442
   PubMedGoogle Scholar
• Howell A. L., Guyre P. M., You K., Fanger M. W. Targeting HIV-1 to FcR on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells. J. Leukoc. Biol. 1994; 55: 385–391
   PubMed Web of Science ®Google Scholar
• Hsieh-Ma S. T., Eaton A. M., Shi T., Ring D. B. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc receptor III. Cancer Res. 1992; 52: 6832–6839
   PubMedGoogle Scholar
• Hubbard A. L., Wilson G., Asgwell G., Stukenbrok H. An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. II. Intracellular fates of the 125I-ligands. J. Cell. Biol. 1979; 83: 65–81
   PubMed Web of Science ®Google Scholar
• Hurwitz E. Specific and nonspecific macromolecule-drug conjugates for the improvement of cancer chemotherapy. Biopolymers 1983; 22: 557–562
   PubMedGoogle Scholar
• Ihle J., Holzer U., Krull F., Dohlsten M., Kalland T., Niethammer D., Dannecker G. E. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res. 1995; 55: 623–628
   PubMedGoogle Scholar
• Jung G., Muller-Eberhard H. J. An in vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol. Today 1988; 9: 257–260
   PubMedGoogle Scholar
• Kaminski M. S., Zasadny K. R., Francis I. R., Milik A. W., Ross C. W., Moon S. D., Crawford S. M., Burgess J. M., Petry N. A., Butchko G. M. Radioimmunotherapy of B-cell lymphoma with 131I-anti-Bl (anti-CD20) antibody. N. Engl. J. Med. 1993; 329: 459–465
   PubMed Web of Science ®Google Scholar
• Katre N. V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 1990; 144: 209–213
   PubMed Web of Science ®Google Scholar
• Kery V., Novotny L., Tihlarik K. Preparation properties and antileukaemic activity of arabinosylcytosine polysaccharide conjugates. Int. J. Biochem. 1990; 22: 1203–1207
   PubMedGoogle Scholar
• King D. J., Turner A., Farnsworth A. P. H., Adair J. R., Owens R. J., Pedley R. B., Baldock D., Proudfoot K. A., Lawson A. D. G., Beeley N. R. A., Millar K., Millican T. A., Boyce B. A., Antoniw P., Mountain A., Begent R. H. J., Shochat D., Yarranton G. T. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 1994; 54: 6176–6185
   PubMed Web of Science ®Google Scholar
• Kopeček J. Synthesis of tailor-made soluble polymeric drug carriers. Recent Advances in Drug Delivery Systems, J. M. Anderson, S. W. Kim. Plenum Press, New York 1984; 41–62
   Google Scholar
• Kopeček J., Duncan R. Targetable polymeric prodrugs. J. Control. Rel. 1987; 6: 315–327
   Google Scholar
• Kopeček J., Kopečková P., Brondsted H., Rathi R., Říhová B., Yeh P., Ikesue K. Polymers for colon-specific drug delivery. J. Control. Rel. 1992; 19: 121–130
   Web of Science ®Google Scholar
• Kopeček J., Rejmanová P., Strohalm J., Ulbrich K., Řihová B., Chytry V., Duncan R., Lloyd J. B. Synthetic polymeric drugs, Czechoslovak Patent Appl. PV 97–85. U.S. Patent 5,037,883, 1985, U.K. Patent 8500209, Australia Patent 51833/86.
   Google Scholar
• Kopeček J., Říhová B., Krinick N. L. Targetable photoactivatable drugs. J. Control. Rel. 1991; 16: 137–144
   Google Scholar
• Kopečkova P., Kopeček J. Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers by azoreductases in vitro. Makromol. Chem. 1990; 191: 2037–2045
   Web of Science ®Google Scholar
• Kranz D. M., Patrick T. A., Brigle K., Spinella M. J., Roy E. J. Conjugates of folate and anti-T-cell receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA 1995; 92: 9057–9061
   PubMed Web of Science ®Google Scholar
• Krolick K. A., Villemez C., Isakson P., Uhr J. W., Vitetta E. S. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc. Natl. Acad. Sci. USA 1980; 77: 5419–5423
   PubMed Web of Science ®Google Scholar
• Kubota T., Yamamoto T., Takahara T., Furukawa T., Ishibiki K., Kitajima M., Shida Y., Nakatsubo H. Targeting cancer chemotherapy using monoclonal antibody (NCC-LU-243) conjugated with mitomycin C. J. Surg. Oncol. 1992; 51: 75–80
   PubMed Web of Science ®Google Scholar
• Lamers C. H., Gratama J. W., Warnaar S. O., Stoter G., Bolhuis R. L. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int. J. Cancer 1995; 60: 450–457
   PubMed Web of Science ®Google Scholar
• Larson S. M., Carrasquillo J. A. Advantages of radioiodine over radioindium labeled monoclonal antibodies for imaging solid tumors. J. Med. Biol. 1988; 15: 231–233
   Google Scholar
• Leamon C. P., Pastan I., Low P. S. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. J. Biol. Chem. 1993; 268: 24847–24854
   PubMed Web of Science ®Google Scholar
• Liu M. A., Kranz D. M., Kurnick J. T., Boyle L. A., Levy R., Eisen H. N. Heterogeneity duplexes target cells for lysis by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1985; 82: 8648–8652
   PubMed Web of Science ®Google Scholar
• Liu M. A., Nussbaum S. R., Eisen H. N. Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells. Science 1988; 239: 395–398
   PubMed Web of Science ®Google Scholar
• Liu Y., Janeway C. A., Jr. Interferon j plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J. Exp. Med. 1990; 172: 1735–1739
   PubMed Web of Science ®Google Scholar
• Longman S. A., Cullis P. R., Choi L., de Jong G., Bally M. B. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother. Pharmacol. 1995; 36: 91–101
   PubMed Web of Science ®Google Scholar
• Mabondzo A., Aussage P., Bartholeyns J., Le Naour R., Raoul H., Romet-Lemonne J.-L., Dormont D. Bispecific antibody targeting of human immunodeficiency virus type 1 (HIV-1) glycoprotein 41 to human macrophages through Fc IgG receptor I mediates neutralizing effects in HIV-1 infection. J. Infect. Dis. 1992; 166: 93–99
   PubMedGoogle Scholar
• Manetti C., Le Doussal J.-M., Rouvier E., Gruaz-Guyon A., Barbet J. Intracellular uptake and catabolism of anti-IgM antibodies and bispecific antibody-targeting hapten by B-lym-phoma cells. Int. J. Cancer 1995; 63: 250–256
   PubMedGoogle Scholar
• Maraveyas A., Epenetos A. A. Targeted immunotherapy. An update with special emphasis on ovarian cancer. Acta Oncol. 1993; 32: 741–746
   PubMed Web of Science ®Google Scholar
• Mathé G., Loc T. B., Bernard J. Effect sur la leucémie LI210 de la souris d une combination par diazotation d'améthoptérine et de gamma globulines de hamsters porteurs de cette leucémie perhétérogreffe. C.R. Acad. Sci. (Paris) 1958; 246: 1626, (in French)
   Google Scholar
• Matzku S., Kirchgessner H., Schirrmacher V. Antibody targeting to the murine lymphoma ESb-MP: increased due to reduced internalization into lymphoma cells as compared to normal lymphoid cells. Int. J. Cancer 1988; 41: 108–114
   PubMed Web of Science ®Google Scholar
• Moan J., Beg K., Kvam E., Western A., Malik Z., Ruck A., Schneckenburger H. Intracellular localization of photosensitizers. Ciba Foundation Symposium 146, Photosensitizing Compounds: Their Chemistry, Biology and Clini-col Use. John Wiley & Sons, Chichester 1989; 95–107
   Google Scholar
• Moolten F. L., Capparell N. J., Zajdel S. H., Cooperband S. R. Anti-tumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by Simian virus 40. J. Natl. Cancer Inst. 1975; 55: 473–477
   PubMed Web of Science ®Google Scholar
• Moran T. M., Usuba O., Kuzu H., Kuzu Y., Schulman J., Bona C. A. Inhibition of multicycle influenza virus replication by hybrid antibody-directed cytotoxic T lymphocyte lysis. J. Immunol. 1991; 146: 321–326
   PubMedGoogle Scholar
• Musuho Y., Hara T., Noguchi T. Preparation of a hybrid of fragment Fab of antibody and fragment A of diphtheria toxin and its cytotoxicity. Biochem. Biophys. Res. Commun. 1979; 90: 320–326
   PubMedGoogle Scholar
• Muzykantov V. R., Atochina E. N., Gavriljuk V., Danilov S. M., Fisher A. B. Immunotargeting of streptavidin to the pulmonary endothelium. J. Nucl. Med. 1994; 35: 1358–1356
   PubMedGoogle Scholar
• Neville D. M., Youle R. J. Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy. Immunol. Rev. 1982; 62: 75–91
   PubMed Web of Science ®Google Scholar
• Oeltmann T. N., Heath E. C. A hybrid protein containing the toxic subunit of ricin and the cell-specific subunit of human chorionic gonadotropin. J. Biol. Chem. 1979; 254: 1028–1032
   PubMedGoogle Scholar
• Omelyanenko V., Kopečková P., Gentry C., Shiah J.-G., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Targeting 1996; 3: 357–373
   PubMed Web of Science ®Google Scholar
• Oseroff A. R., Ohuoha D., Hadan T., Bommer J. C., Yarmush M. L. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc. Natl. Acad. Sci. USA 1986; 83: 8744–8788
   PubMed Web of Science ®Google Scholar
• Ouchi T., Fujimo A., Tanaka K. Synthesis and antitumor activity of conjugates of poly(alphamalic acid) and 5-fluorouracils bound via ester, amide or carbamoyl bonds. J. Control. Rel. 1990; 12: 143–153
   Web of Science ®Google Scholar
• Paganelli G., Magnani P., Zito F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991; 51: 5960–5966
   PubMed Web of Science ®Google Scholar
• Pastan I., Willingham M. C., Fitz Gerald D. J. P. Immunotoxins. Cell 1986; 47: 641–648
   PubMed Web of Science ®Google Scholar
• Paya C. V., McKean D. J., Segal D. M., Schoon R. A., Showalter S. D., Leibson P. J. Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity. J. Immunol. 1989; 142: 666–671
   PubMedGoogle Scholar
• Pedley R. B., Boden J. A., Boden R., Begent R. H. J., Turner A., Heines A. M. R., King D. J. The potential for enhance tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer 1994; 70: 1126–1130
   PubMed Web of Science ®Google Scholar
• Perez P., Hoffman R. W., Shaw S., Bluestone J. A., Segal D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316: 354–356
   PubMed Web of Science ®Google Scholar
• Pimm M. V., Clegg J. A., Garnett M. C., Baldwin R. W. Biodistribution and tumour localization of a methotrexate-monoclonal-antibody 79 IT/ 36 conjugate in nude mice with human tumour xenografts. Int. J. Cancer 1988; 41: 886–891
   PubMed Web of Science ®Google Scholar
• Pitt G. G., Gratzl M. M., Jeffcoat A. R., Zweidinger R., Schindler A. Sustained drug delivery systems. II. Factors affecting release rates from poly (E-caprolactons) and related biodegradable polyesters. J. Pharm. Sci. 1979; 68: 1534–1539
   PubMed Web of Science ®Google Scholar
• Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger Ch. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B., Matthews D. C., Fisher L. D., Bernstein I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 1993; 329: 1219–1224
   PubMed Web of Science ®Google Scholar
• Press O. W., Martin P. J., Thorpe P. E., Vitetta E. S. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. Immunol. 1988; 141: 4410–4417
   Google Scholar
• Priebe W., Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol. Ther. 1993; 60: 215–234
   PubMed Web of Science ®Google Scholar
• Raso V. Antibody-mediated delivery of toxic molecules to antigen bearing target cells. Immunol. Rev. 1982; 62: 93–111
   PubMedGoogle Scholar
• Raso V., Griffin T. Specific cytotoxicity of a human immunoglobulin-directed Fab-ricin A chain conjugate. J. Immunol. 1980; 125: 2610–2616
   PubMedGoogle Scholar
• Rathi R. C., Kopečková P., Říhová B., Kopeček J. N-(2-hydroxypropyl)-methacrylamide copolymers containing pendant saccharide moieties. Synthesis and bioadhesive properties. J. Polym. Sci. Part A 1991; 29: 1895–1902
   Web of Science ®Google Scholar
• Rejmanová P., Pohl J., Baudyš M., Kostka V., Kopeček J. Degradation of oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 1983; 184: 2009–2020
   Web of Science ®Google Scholar
• Říhová B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 1995; 40: 367–384
   PubMedGoogle Scholar
• Říhová B., Bilej M., Větvička V., Ulbrich K., Strohalm J., Kopeček J., Duncan R. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing Adriamycin. Immunogenicity and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 1989a; 10: 335–342
   PubMed Web of Science ®Google Scholar
• Říhová B., Jegorov A., Strohalm J., Matha V., Rossmann P., Fornsek L., Ulbrich K. Antibody-targeted cyclosporin A. J. Control. Rel. 1992a; 19: 25–40
   Google Scholar
• Říhová B., Kopeček J. Biological properties of targetable poly[N-(2-hydroxypropyl) methacrylamide]-antibody conjugates. J. Control. Rel. 1985; 2: 289–310
   Google Scholar
• Říhová B., Kopeček J., Kopečková-Rejmanová P., Strohalm J., Plocová D., Semorádová H. Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers. J. Chromatogr. Biomed. Appl. 1986; 376: 221–233
   Google Scholar
• Říhová B., Kopeček J., Ulbrich K., Prospíšil M., Mančal P. Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 1984; 5: 143–148
   PubMed Web of Science ®Google Scholar
• Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., Kopeček J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immuno-pathol. 1988; 46: 100–114
   PubMedGoogle Scholar
• Říhová B., Krinick N. L., Kopeček J. Targetable photoactivatable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies. J. Control. Re. 1993; 25: 71–87
   Google Scholar
• Říhová B., Rathi R. C., Kopečková P., Kopeček J. Bioadhesion of carbohydrate-containing HPMA copolymers to GI tract of guinea pigs. Int. J. Pharm. 1992b; 87: 105–116
   Google Scholar
• Říhová B., Strohalm J., Plocová D., Šubr V., Šrogl J., Jelínková M., Sírová M., Ulbrich K. Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A. J. Control. Re. 1996; 40: 303–319
   Web of Science ®Google Scholar
• Říhová B., Strohalm J., Plocová D., Ulbrich K. Selectivity of antibody-targeted anthra-cycline antibiotics on T lymphocytes. J. Bioact. Compatible Polym. 1990; 5: 249–266
   Google Scholar
• Říhová B., Vereš K., Fornsek L., Ulbrich K., Strohalm J., Větvička V., Bilej M., Kopeček J. Action of polymeric prodrugs based on N-(2-hy droxypropyl)methacrylamide copolymers. II. Body distribution and T-cell accumulation of free and polymer-bound [125I] daunomycin. J. Control. Re. 1989b; 10: 37–49
   Web of Science ®Google Scholar
• Říhová B., Větvička V., Strohalm J., Ulbrich K., Kopeček J. Action of polymeric prodrugs based on N-(2-hydroxypropyl)methacrylamide copolymers. I. Suppression of the antibody response and proliferation of mouse splenocytes in vitro. J. Control. Rel. 1989c; 9: 21–32
   Google Scholar
• Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Symp. 1975; 51: 135–144
   Google Scholar
• Rojanasakul T., Wang L. Y., Malanga C. J., Ma J. K. H., Liaw S. Targeted gene delivery to alveolar macrophages via Fc receptor-mediated endocytosis. Pharm. Res. 1994; 11: 1731–1736
   PubMed Web of Science ®Google Scholar
• Roth J. A., Ames R. S., Restrepo C., Scuderi P., Scannon P. J., Lee H. M. Human tumor antigen expression is induced on murine 3T3 cells following transformation by human oncogenes. Fed. Proc. 1985; 44: 550–551
   Google Scholar
• Rowland G. F., O'Neill G. J., Davies D. A. L. Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 1975; 255: 487–488
   PubMed Web of Science ®Google Scholar
• Ryser H. J. P., Shen Ch W., Merk F. B. Membrane transport of macromolecules: new carrier functions of proteins and poly (amino acids). Life Sci. 1978; 22: 1253–1260
   PubMed Web of Science ®Google Scholar
• Schwartz A. L., Fridovich S. E., Lodish H. F. Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J. Biol. Chem. 1982; 257: 4230–4237
   PubMed Web of Science ®Google Scholar
• Scott C. F., Jr., Lambert J. M., Kalish R. S., Morimoto C., Schlossman S. F. Human T cells can be directed to lyse tumor targets through the alternative activation/T11-E rosette receptor pathway. J. Immunol. 1988; 140: 8–14
   PubMedGoogle Scholar
• Sela M., Hurwitz E. Conjugates of antibodies with cytotoxic drugs. Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer, C. W. Vogel. Oxford University Press, Oxford, New York 1987; 189–216
   Google Scholar
• Seymour L., Duncan R., Strohalm J., Kopeček J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 1987; 21: 1341–1358
   PubMed Web of Science ®Google Scholar
• Seymour L. W., O'Harre K. B., Duncan R., Strohalm J., Ulbrich K. First- and second-order drug targeting to hepatic melanoma metastases. Br. J. Cancer 1993; 63: 833–838
   Google Scholar
• Shepherd V. L. Intracellular pathways and mechanisms of sorting in receptor-mediated en-docytosis. TIPS 1989; 10: 458–462
   PubMed Web of Science ®Google Scholar
• Shin S.-U., Friden P., Moran M., Olson T., Kang Y.-S., Pardridge W. M., Morrison S. L. Transferrin-antibody fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. USA 1995; 92: 2820–2824
   PubMed Web of Science ®Google Scholar
• Staerz U. D., Bevan M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. USA 1986; 83: 1453–1457
   PubMed Web of Science ®Google Scholar
• Staerz U. D., Kanagawa O., Bevan M. J. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628–631
   PubMed Web of Science ®Google Scholar
• Stancovski I., Schindler D. G., Waks T., Yarden Y., Sela M., Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 1993; 151: 6577–6582
   PubMed Web of Science ®Google Scholar
• Štastn M., Říhová B., Strohalm J., Ulbrich K. in press. Comparison of the binding kinetics of antibody-targeted HPMA-bound doxorubicin in vitro and in vivo. J. Control. Rel.
   Google Scholar
• Steele J. K., Liu D., Stammers A. T., Whitney S., Levy J. G. Suppressor deletion therapy: Selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells. Cancer Immunol. Immunother. 1988; 26: 125–131
   PubMedGoogle Scholar
• Steinman R. M., Melleman I. S., Muller W. A., Cohn Z. A. Endocytosis and recycling of plasma membrane. J. Cell Biol. 1983; 96: 1–13
   PubMed Web of Science ®Google Scholar
• Šubr V., Kopeček J., Pohl J., Baudyš M., Kostka V. Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)methacrylamide copolymers by mixture of lysosomal enzymes. J. Control. Rel. 1988; 8: 133–140
   Google Scholar
• Suzuki S., Uno S., Fukuda Y., Aoki Y., Masuko T., Hashimoto Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br. J. Cancer 1995; 72: 663–668
   PubMed Web of Science ®Google Scholar
• Tanaka H., Satake-Ishikawa R., Ishikawa M. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethyleneglycol in rats. Cancer Res. 1991; 51: 3710–3714
   PubMed Web of Science ®Google Scholar
• Tazzari P. L., Zhang S., Chen Q., Sforzini S., Bolognesi A., Stirpe F., Xie H., Moretta A., Ferrini S. Targeting of saporin to CD25-positive normal and neoplastic lymphocyte by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation. Br. J. Cancer 1993; 67: 1248–1253
   PubMedGoogle Scholar
• Thorpe P. E., Ross W. C. J. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol. Rev. 1982; 62: 119–158
   PubMedGoogle Scholar
• Trouet A., Deprez-De Campeneere D., Baurain R., Huybrechts M., Zenenberh A. Drugs Carriers in Biology and Medicine, G. Gregoriadis. Academic Press, New York 1979; 87
   Google Scholar
• Uchida T., Mekada E., Okada Y. Hybrid toxin of the A chain of ricin and a subunit of Wisteria floribunda lectin. Possible importance of the hydrophobic region for entry of toxin into the cell. J. Biol. Chem. 1980; 255: 6687–6693
   PubMedGoogle Scholar
• van Dijk J., Zegveld S. T., Fleuren G. J., Warnaar S. O. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/ G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int. J. Cancer 1991; 48: 738–743
   PubMedGoogle Scholar
• Vitetta E. S., Krolick K. A., Uhr J. W. Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol. Rev. 1982; 62: 159–183
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till J., Newman P., Clark P., Collins R., Cunningham D., Gethie V., Uhr J. W., Thorpe P. E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991; 51: 4052–4061
   PubMed Web of Science ®Google Scholar
• Volfová I., Říhová B., Větvička V., Rossmann P., Ulbrich K. Biocompatibility of biopolymers. J. Bioact. Compat. Polym. 1992; 7: 175–179
   Google Scholar
• Wade R., Whisson M. E., Szekerke M. Some serum protein nitrogen mustard complexes with high chemotherapeutic selectivity. Nature 1961; 215: 1303–1304
   Google Scholar
• Waldmann T. A. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 1657–1662
   PubMed Web of Science ®Google Scholar
• Wall D. A., Wilson G., Hubbard A. L. The galactose-specific recognition system of mammalian liver: The route of ligand internalization in rat hepatocytes. Cell 1980; 21: 79–93
   PubMed Web of Science ®Google Scholar
• Weiner L. M., Holmes M., Adams G. P., LaCretta F., Watts P., dePalazzo I. G. A humor tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD 16. Cancer Res. 1993; 53: 94–100
   PubMed Web of Science ®Google Scholar
• White R., Lowrie L., Stork J., et al. Targeted enzyme therapy of experimental glomerulonephritis in rats. J. Clin. Invest. 1991; 87: 1819–1827
   PubMedGoogle Scholar
• Wiener G. J., Hillstrom J. R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol. 1991; 147: 4035–4044
   PubMedGoogle Scholar
• Wu G. Y., Wu Ch. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 1988; 262: 14621–14624
   Google Scholar
• Yokota T., Milenic D. E., Whitlow M. J., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992; 52: 3402–3408
   PubMed Web of Science ®Google Scholar
• Zimmer A. M., Kaplan E. H., Kazikiewicz J. M., Goldman-Leikin R., Gilyon K. A., Dykewicz M. S., Spies S. M., Rosen S. T. Pharmacokinetics of I-131 T101 monoclonal antibody in patients with chronic lymphocytic leukemia. Antibody Immunoconjug. Radiopharm. 1988; 1: 291–303
   Google Scholar